Show simple item record

dc.contributor.authorPatel, Minal K
dc.contributor.authorBergeri, Isabel
dc.contributor.authorBresee, Joseph S
dc.contributor.authorCowling, Benjamin J
dc.contributor.authorCrowcroft, Natasha S
dc.contributor.authorFahmy, Kamal
dc.contributor.authorHirve, Siddhivinayak
dc.contributor.authorKang, Gagandeep
dc.contributor.authorKatz, Mark A
dc.contributor.authorLanata, Claudio F
dc.contributor.authorL'Azou Jackson, Maïna
dc.contributor.authorJoshi, Sudhir
dc.contributor.authorLipsitch, Marc
dc.contributor.authorMwenda, Jason M
dc.contributor.authorNogareda, Francisco
dc.contributor.authorOrenstein, Walter A
dc.contributor.authorOrtiz, Justin R
dc.contributor.authorPebody, Richard
dc.contributor.authorSchrag, Stephanie J
dc.contributor.authorSmith, Peter G
dc.contributor.authorSrikantiah, Padmini
dc.contributor.authorSubissi, Lorenzo
dc.contributor.authorValenciano, Marta
dc.contributor.authorVaughn, David W
dc.contributor.authorVerani, Jennifer R
dc.contributor.authorWilder-Smith, Annelies
dc.contributor.authorFeikin, Daniel R
dc.date.accessioned2021-06-21T14:45:55Z
dc.date.available2021-06-21T14:45:55Z
dc.date.issued2021-06-01
dc.identifier.urihttp://hdl.handle.net/10713/16056
dc.description.abstractPhase 3 randomized-controlled trials have provided promising results of COVID-19 vaccine efficacy, ranging from 50 to 95% against symptomatic disease as the primary endpoints, resulting in emergency use authorization/listing for several vaccines. However, given the short duration of follow-up during the clinical trials, strict eligibility criteria, emerging variants of concern, and the changing epidemiology of the pandemic, many questions still remain unanswered regarding vaccine performance. Post-introduction vaccine effectiveness evaluations can help us to understand the vaccine's effect on reducing infection and disease when used in real-world conditions. They can also address important questions that were either not studied or were incompletely studied in the trials and that will inform evolving vaccine policy, including assessment of the duration of effectiveness; effectiveness in key subpopulations, such as the very old or immunocompromised; against severe disease and death due to COVID-19; against emerging SARS-CoV-2 variants of concern; and with different vaccination schedules, such as number of doses and varying dosing intervals. WHO convened an expert panel to develop interim best practice guidance for COVID-19 vaccine effectiveness evaluations. We present a summary of the interim guidance, including discussion of different study designs, priority outcomes to evaluate, potential biases, existing surveillance platforms that can be used, and recommendations for reporting results.en_US
dc.description.urihttps://doi.org/10.1016/j.vaccine.2021.05.099en_US
dc.language.isoenen_US
dc.publisherElsevier Ltd.en_US
dc.relation.ispartofVaccineen_US
dc.rightsCopyright © 2021.en_US
dc.subjectCOVID-19en_US
dc.subjectVaccinationen_US
dc.subjectVaccine effectivenessen_US
dc.titleEvaluation of post-introduction COVID-19 vaccine effectiveness: Summary of interim guidance of the World Health Organizationen_US
dc.typeArticleen_US
dc.identifier.doi10.1016/j.vaccine.2021.05.099
dc.identifier.pmid34119350
dc.source.countryUnited Kingdom
dc.source.countryUnited States
dc.source.countryNetherlands


Files in this item

Thumbnail
Name:
Publisher version

This item appears in the following Collection(s)

Show simple item record